secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLARGO, INC. (BLGO)
CIK:        0000880242
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001437749-25-023293
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag
--------------------------------------------------------------------------------

- Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.
- Cellinity battery signed four MOUs with JV partners; each factory >$100M build, $500M annual revenue capacity; targets enterprise value >$2B.
- First paid PFAS treatment project in New Jersey underway; AEC removes PFAS below 4 ppt; CEO named to U.S. Dept of Commerce ETTAC.
- ONM (Pooph) sales decline led to increased AR, lower cash, downward stock pressure; payback arrangement and new Pooph ads launched.
- BLEST engineering revenues grew 152% YoY in Q1 2025; potential multimillion-dollar projects in pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/880242/000143774925023293/0001437749-25-023293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/880242/000143774925023293/blgo20250723_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-023293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer